News | May 16, 2024

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) – After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival...

News | April 29, 2024

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion Deciphera Shareholders to Receive $25.60 per Share in Cash Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets Will Reinforce ONO...

News | April 29, 2024

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem –First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved– –Potential Approval Early Q4 2024–...

News | April 10, 2024

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) – Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity Investment from Johnson &...

News | April 11, 2024

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer – Arvinas to receive a $150 million upfront...

News | March 7, 2024

CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference Drug Combination’s Unique Mechanism of Action Enables Reactivation...